HAIFA, Israel, March 7, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc . (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR) announced today that over the next month, company executives will present at three leading financial events. The presentations follow the recent announcement of positive pre-clinical data from a muscle injury study, successful raise of gross proceeds of more than $40 million in a public offering on Nasdaq, as well as the news announced in January regarding the completion of a parallel scientific advisory process with the EMA and FDA regarding the company's planned clinical development program for PLX-PAD. As previously announced, Pluristem plans to conduct two clinical studies of PLX-PAD and to file the necessary regulatory documentation requesting the joint approval of the FDA-EMA for a Phase II/III study of PLX-PAD for critical limb ischemia (CLI) and a joint approval of the FDA and the Paul Ehrlich Institute (PEI) in Germany to conduct a Phase II study for Intermittent Caludication (IC). "Since our announcement back in January regarding the completion of the parallel scientific advisory process with the EMA and FDA and the completion of the recent fundraising, we have seen a rapid increase in interest in our Company from the financial, investment and scientific communities," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "These presentations will enable us to discuss the competitive advantages of our platform, as well our planned product portfolio, with a number of strategic target audiences." Over the next month, Pluristem will be presenting at the following conferences:
Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com , the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882 Safe Harbor Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we say that we plan to conduct two clinical studies and file the regulatory documentation to obtain the required approvals for that, or when we say that data from phase I/IIa studies indicate that PLX-PAD, is potentially safe and effective for the treatment of end stage Peripheral Artery Disease and that our pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc. William Prather R.Ph., M.D. Sr. VP Corporate Development 1-303-883-4954 William.PratherMD@pluristem.com Daya Lettvin, Director Investor & Media Relations +972-54-674-5580 email@example.com Media Contact: Matthew Krieger Ruder Finn - for Pluristem +972-54-467-6950 firstname.lastname@example.org